Castelgrande Lectures. New cancer therapies: a conference by Douglas Hanahan


Institutional Communication Service

19 February 2019

Douglas Hanahan, Professor at the Swiss Federal Institute of Technology of Lausanne and Director of the Swiss Institute for Experimental Cancer Research (ISREC), will be the guest of the first Castelgrande Lecture on Monday, April 15, at 5 pm in Castelgrande Hall, Bellinzona. The annual conference is promoted by the Institute of Oncology Research (IOR, affiliated to USl) with the aim of strengthening connections between Ticino, the local institutions, and the scientific community, while promoting love for science and emphasising its importance for quality healthcare, and the region’s economic development.

During his lecture open to the public and in english, Prof. Hanahan will discuss the challenges that future generations of scientists, doctors, politicians, and the community will have to face in order to defeat the disease in the next few decades.

Prof. Hanahan’s research led to the discovery of a process named angiogenic switch which supports the growth of the tumour through the production of new blood vessels. His work has also inspired the clinical development of therapies that can halt the disease.

Prof. Hanahan is internationally recognised as an excellent scientific disseminator and promoter of biomedical research. Thanks to his contribution, the role of the Swiss Institute for Experimental Cancer Research of Lausanne has significantly strengthen worldwide in the field of oncology research, and is now setting an example in Switzerland. The lecture “Hallmarks of Cancer: Thinking globally about new cancer therapies” will launch the Castelgrande Lectures, that will feature every year a leading scientist in biomedical sciences, and in particular in the field of oncology.

The event is held thanks to the support of the IBSA Foundation for scientific research and the City of Bellinzona.